Infant Botulism Treatment and Prevention Program (IBTPP)
The mission of the IBTPP is to provide and improve the treatment of infant botulism and to prevent infant botulism and related diseases. The IBTPP is a California Department of Public Health program within the Center for Infectious Disease, Division of Communicable Disease Control.
About the disease
Infant Botulism is an orphan ("rare") disease that affects infants primarily between one and 52 weeks of age. First recognized in 1976 in California, infant botulism occurs globally and is the most common form of human botulism in the United States.
Infant botulism is a novel form of human botulism in which ingested spores of Clostridium botulinum colonize and grow in the infant's large intestine and produce botulinum neurotoxin in it. The action of the toxin in the body produces constipation, weakness (notably of gag, cry, suck and swallow), loss of muscle tone, and ultimately, flaccid ("limp") paralysis. Affected infants have difficulty feeding and often, breathing. However, in the absence of complications, patients recover completely from the disease. After an approximately 15-year development period, in October 2003 the U.S. Food and Drug Administration licensed to the California Department of Public Health its public service orphan drug for the treatment of infant botulism, Human Botulism Immune Globulin, under the proprietary name BabyBIG(R).
For complete information about the treatment and prevention of infant botulism please see the Infant Botulism Treatment and Prevention Program Website. The IBTPP Website provides guidelines for physicians, pharmacists, laboratory scientists, and parents.
For suspected cases of Infant Botulism, consultation, and to obtain BabyBIG(R), physicians should immediately telephone 510-231-7600 (24/7/365).
For non-urgent questions, contact the IBTPP via its email address: email@example.com